Alabama Senate Bill SB20

Alabama 2023 Regular Session

• Introduced: 2/27/23
• Refer: 2/27/23
• Report Pass: 3/22/23

Caption

Relating to the Board of Pharmacy; to amend Section 34-23-32 of the Code of Alabama 1975, requiring a manufacturer, bottler, packager, wholesale drug distributor, and other entities in the supply chain for pharmaceutical products to obtain an annual permit from the board; to require each permit holder to designate a representative of the permit holder who would be required to register with the board; and to provide for an additional annual registration fee.

Impact

The impact of SB20 includes a significant increase in regulatory requirements for entities operating within the pharmaceutical sector. By introducing the need for annual permits and specific registration of representatives, the bill aims to mitigate risks associated with drug distribution and improve public health standards. Entities that fail to comply with these regulations may face penalties, which could influence operational practices in the industry and potentially increase costs related to compliance for manufacturers and distributors.

Summary

SB20 addresses regulatory measures related to the pharmaceutical supply chain in Alabama. Specifically, it mandates that manufacturers, bottlers, packagers, wholesale drug distributors, and other entities involved in the distribution of pharmaceutical products obtain an annual permit from the Board of Pharmacy. This requirement aims to tighten oversight of pharmaceutical operations and ensure compliance with state regulations concerning drug distribution. Additionally, each permit holder must designate a representative who will be responsible for registering with the Board, enhancing accountability within the supply chain.

Contention

While supporters of SB20 argue that the increased regulation is essential for patient safety and effective pharmaceutical oversight, there may be concerns regarding the additional burdens placed on manufacturers and distributors. Critics might voice apprehensions about the feasibility of compliance, particularly for smaller companies, which may lack the resources to meet new requirements. The discussion around these provisions hints at a potential divide between fostering stringent public health regulations and ensuring that industry operations remain feasible and economically viable.